Ketogenic diet as elective treatment in patients with drug-unresponsive hyperinsulinemic hypoglycemia caused by glucokinase mutations.
Cognitive outcome
Epilepsy
Hyperinsulinemic hypoglycemia
Hypoglycemia
Ketogenic diet
Neurodevelopment
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
11 10 2021
11 10 2021
Historique:
received:
09
04
2021
accepted:
19
09
2021
entrez:
12
10
2021
pubmed:
13
10
2021
medline:
3
11
2021
Statut:
epublish
Résumé
Hyperinsulinemic hypoglycemia (HI) is the most frequent cause of recurrent hypoglycemia in children. Despite diagnostic and therapeutic advances, it remains an important cause of morbidity, leading to neurological complications, such as psychomotor retardation and epilepsy. Patients with diffuse drug-unresponsive HI manifest neurological impairment and neurobehavioral problems, even though surgically treated with a near-total pancreatectomy. Based on the analogies between HI and GLUT1 deficiency, both presenting with neuroglycopenia and lack of alternative cerebral energy sources, we administered a ketogenic diet (KD) in three drug-unresponsive GCK-HI patients with the aim of preserving neurodevelopment and avoiding the need of a near-total pancreatectomy. They presented recurrent symptomatic hypoglycemia, intellectual disability and refractory epilepsy. Patients were treated with classical KD for 79, 27 and 18 months, respectively. All patients became asymptomatic in a few days and showed an important improvement of the alert state. Epilepsy disappeared and no appearance of novel hypoglycemic lesions was detected with a brain MRI. Cognitive and adaptive abilities rapidly improved and normalized. IQ rose significantly from 81 to 111 (p = 0.04) in patient 1, from 82 vs 95 (p = 0.04) in patient 2, from 60 to 90 (p = 0.04) in patient 3. We demonstrated the safety and efficacy of KD in the treatment of drug-unresponsive GCK-HI at a short and long-term. The neuroprotective effects of KD determined the recovery from epilepsy and intellectual disabilities and averted the need of a near-total pancreatectomy. All patients and their families reported an improvement of physical and psychosocial well-being, with a substantial improvement of their quality of life. These results might change the course and the quality of life of these patients and their families, having a relevant impact on human lives. Therefore, KD might be considered the elective treatment in unresponsive forms of GCK-HI.
Sections du résumé
BACKGROUND
Hyperinsulinemic hypoglycemia (HI) is the most frequent cause of recurrent hypoglycemia in children. Despite diagnostic and therapeutic advances, it remains an important cause of morbidity, leading to neurological complications, such as psychomotor retardation and epilepsy. Patients with diffuse drug-unresponsive HI manifest neurological impairment and neurobehavioral problems, even though surgically treated with a near-total pancreatectomy. Based on the analogies between HI and GLUT1 deficiency, both presenting with neuroglycopenia and lack of alternative cerebral energy sources, we administered a ketogenic diet (KD) in three drug-unresponsive GCK-HI patients with the aim of preserving neurodevelopment and avoiding the need of a near-total pancreatectomy. They presented recurrent symptomatic hypoglycemia, intellectual disability and refractory epilepsy. Patients were treated with classical KD for 79, 27 and 18 months, respectively.
RESULTS
All patients became asymptomatic in a few days and showed an important improvement of the alert state. Epilepsy disappeared and no appearance of novel hypoglycemic lesions was detected with a brain MRI. Cognitive and adaptive abilities rapidly improved and normalized. IQ rose significantly from 81 to 111 (p = 0.04) in patient 1, from 82 vs 95 (p = 0.04) in patient 2, from 60 to 90 (p = 0.04) in patient 3.
CONCLUSIONS
We demonstrated the safety and efficacy of KD in the treatment of drug-unresponsive GCK-HI at a short and long-term. The neuroprotective effects of KD determined the recovery from epilepsy and intellectual disabilities and averted the need of a near-total pancreatectomy. All patients and their families reported an improvement of physical and psychosocial well-being, with a substantial improvement of their quality of life. These results might change the course and the quality of life of these patients and their families, having a relevant impact on human lives. Therefore, KD might be considered the elective treatment in unresponsive forms of GCK-HI.
Identifiants
pubmed: 34635134
doi: 10.1186/s13023-021-02045-3
pii: 10.1186/s13023-021-02045-3
pmc: PMC8507241
doi:
Substances chimiques
Pharmaceutical Preparations
0
Glucokinase
EC 2.7.1.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
424Informations de copyright
© 2021. The Author(s).
Références
N Engl J Med. 1999 Apr 15;340(15):1169-75
pubmed: 10202168
J Pediatr Endocrinol Metab. 2013;26(3-4):301-8
pubmed: 23327786
Curr Neurol Neurosci Rep. 2013 Apr;13(4):342
pubmed: 23443458
Diabet Med. 2007 Dec;24(12):1393-9
pubmed: 17976205
Clin Endocrinol (Oxf). 2014 Nov;81(5):679-88
pubmed: 24383515
J Diabetes Complications. 2020 May;34(5):107557
pubmed: 32199771
Epilepsia Open. 2020 Nov 25;5(4):596-604
pubmed: 33336130
J Inherit Metab Dis. 2017 Jul;40(4):531-542
pubmed: 28656511
N Engl J Med. 1991 Sep 5;325(10):703-9
pubmed: 1714544
Hum Brain Mapp. 2014 May;35(5):2297-309
pubmed: 23897639
N Engl J Med. 1998 Jan 22;338(4):226-30
pubmed: 9435328
Front Endocrinol (Lausanne). 2013 May 20;4:60
pubmed: 23730298
J Pediatr Nurs. 2005 Apr;20(2):109-18
pubmed: 15815570
J Child Neurol. 2000 Dec;15(12):787-90
pubmed: 11198492
Dev Med Child Neurol. 2019 Apr;61(4):451-457
pubmed: 30246438
Front Neurol. 2021 Mar 12;12:643105
pubmed: 33776895
Pediatrics. 2001 Mar;107(3):476-9
pubmed: 11230585
Eur J Endocrinol. 2003 Jul;149(1):43-51
pubmed: 12824865
Pediatr Endocrinol Rev. 2009 Mar;6(3):424-30
pubmed: 19396028
Curr Treat Options Neurol. 2014 May;16(5):291
pubmed: 24634059
J Clin Endocrinol Metab. 2015 Nov;100(11):4133-9
pubmed: 26327482
Dev Med Child Neurol. 2013 Feb;55(2):162-6
pubmed: 23205874
Epilepsia. 2007 Jan;48(1):43-58
pubmed: 17241207
Epilepsia Open. 2020 Aug 13;5(3):354-365
pubmed: 32913944
PLoS One. 2014 May 19;9(5):e98054
pubmed: 24840042
Diabetes. 2009 Jun;58(6):1419-27
pubmed: 19336674
Diabetes. 2004 Aug;53(8):2164-8
pubmed: 15277402
Epilepsia Open. 2018 May 21;3(2):175-192
pubmed: 29881797
Pediatrics. 2008 Jul;122(1):65-74
pubmed: 18595988
Diabetes Care. 2012 Feb;35(2):198-203
pubmed: 22190679
J Pediatr Surg. 2019 Jan;54(1):27-32
pubmed: 30343978
Orphanet J Rare Dis. 2015 Sep 24;10:120
pubmed: 26399329
N Engl J Med. 2014 Mar 20;370(12):1131-7
pubmed: 24645945
J Pediatr Psychol. 2003 Apr-May;28(3):185-90
pubmed: 12654943
Pediatr Neurol. 2017 Mar;68:35-39
pubmed: 28188074